Drugs / PEP08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06973863 | Aug 2025 → Dec 2027 expected | chromosomal disorder, neoplasm | PharmaEngine | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | PharmaEngine | Regulatory PharmaEngine announces South Korea's MFDS approval of PEP08 Phase I clinical trial for solid tumor cancers pharmaengine.com ↗
PharmaEngine, Inc. (TWO:4162) announces MFDS (South Korea's Ministry of Food and Drug Safety) has approved PEP08 Phase I clinical trial for solid tumor cancers. |
| 2025-08-20 | PharmaEngine | Regulatory PharmaEngine announces TFDA approval of PEP08 Phase 1 clinical trial for solid tumor cancers pharmaengine.com ↗
PharmaEngine, Inc. (TWO:4162) announces TFDA (Taiwan Food and Drug Administration) has approved PEP08 Phase 1 clinical trial for solid tumor cancers. |
| 2025-07-22 | PharmaEngine | Regulatory PharmaEngine announces Phase I clinical study of PEP08 has been approved by Australia HREC and acknowledged by Australia TGA pharmaengine.com ↗
PharmaEngine, Inc. (TWO:4162) announces PEP08 Phase I clinical trial in solid tumors has been approved by Australia HREC (Human Research Ethics Committee) and acknowledged by Australia TGA (Therapeutic Goods Administration). |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06973863 ↗ |
| Action | Inhibit | “PRMT5 inhibitor” NCT06973863 ↗ |
| Route | Oral | “PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.” NCT06973863 ↗ |
| Target | PRMT5 | “PRMT5 inhibitor” NCT06973863 ↗ |